ArticleBMC cancer2014

Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.

Xing-Ming Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.